Sale of Alturix to Kelso Pharma
Alturix - based in Milton Keynes - is a pharma company which currently sells seven branded medicines, with a further two pipeline products expected to launch in the next 12 months. Its products cover a range of therapeutic areas, including central nervous system, respiratory disease, and endocrinology.
Alturix aims to supply branded specialty medicines that provide patient benefit and a reduced cost burden to the NHS, a philosophy shared by Kelso Pharma, which has a highly complementary portfolio of products.
Kelso Pharma is a specialty pharma business based in the UK. It is backed by Apposite Capital, a UK fund focused solely on healthcare investments.
“We very much appreciated the hands-on and dedicated support of the BDO Life Sciences team. Their knowledge of the sector and understanding of our buyer group was fundamental to the smooth preparation phase, and ultimately the successful execution of the process. Importantly for us, we enjoyed their personable but proactive working style throughout.”
Simon Clough, Co-Founder of Alturix
“My late father-in-law shaped the first foundation steps of this company some 27 years ago. Over time, coupled with an unrelenting desire for growth, it has grown each year and since his passing in 2014, the company has transformed and transitioned into what is ALTURiX today, the result being far from what I am sure John could have imagined possible. Fit was a critical aspect in deciding the future of the company and we are pleased to be handing ALTURiX over to Dr Tom Stratford and welcome his capable team at Kelso Pharma. Kelso Pharma is ideally structured, suitably resourced and culturally aligned to drive the company further on its exciting growth trajectory and we believe that this is in the best future interests of both patients and prescribers alike."
Simon Fisher, Co-Founder, Alturix